The cost to the United Kingdom National Health Service of managing erectile dysfunction: The impact of sildenafil and prescribing restrictions

PharmacoEconomics

Volumn 20, Issue 13, 2002, Pages 879-889

  Wilson, E C F ^a   McKeen, E S ^b   Scuffham, P A ^a   Brown, M C J ^b   Wylie, K ^c   Hackett, G ^d  

^a UNIVERSITY OF YORK   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PAPAVERINE; PROSTAGLANDIN E1; SILDENAFIL; YOHIMBINE;

ADULT; ARTICLE; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ERECTILE DYSFUNCTION; GENERAL PRACTICE; HEALTH CARE COST; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NATIONAL HEALTH SERVICE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; UNITED KINGDOM;

EID: 0036033848     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220130-00002     Document Type: Article

References (43)

1. Wagner G, Saenz de Tejada I. Update on male erectile dysfunction. BMJ 1998 Feb; 316 (7132): 678-82
2. Hanson-Divers C, Jackson SE, Lue TF, et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998 May; 159 (5): 1541-7
3. Read S, King M, Watson J. Sexual dysfunction in primary medical care: Prevalence, characteristics and detection by the general practitioner. J Public Health Med 1997 Dec; 19 (4): 387-91
4. Dunn KM, Croft PR, Hackett GI. Sexual problems: A study of the prevalence and need for health care in the general population. Fam Pract 1998; 15 (6): 519-24
5. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994 Jan; 151 (1): 54-61
6. Shabsigh R, Alexandre L, Bay Nielson H, et al. Economical aspects of erectile dysfunction. In: Jardin A, Wagner G, Khoury S, et al., editors. Proceedings of the 1st International Consultation on Erectile Dysfunction; 1999 July 1-3; Paris. Paris: Health Publication Ltd, 2000: 55-64
7. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: Clinical and hormonal factors. J Am Geriatr Soc 1988: 36 (6): 511-9
8. Mulligan T, Katz PG. Why aged men become impotent. Arch Intern Med 1989 Jun; 149 (6): 1365-6
9. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995 Nov; 22 (4): 699-709
10. Slag M, Morley J, Elson M, et al. Impotence in medical clinic outpatients. JAMA 1983; 249 (13): 1736-40
11. Action on Smoking and Health. Warning: Smoking Causes Male Impotence; Smoking and Male Sexual Problems [Online]. Available from URL: http://www.ash.org.uk/html/health/html/impotent.html [Accessed 2000 Oct 19]
12. NIH consensus conference. Impotence: NIH consensus development panel on impotence. JAMA 1993 Jul; 270: 83-90
13. Erectile Dysfunction Alliance. UK Management Guidelines for Erectile Dysfunction [Pamphlet]. Approved by the Council of the British Association of Urological Surgeons and by the Association for Genitourinary Medicine. London: Royal Society of Medicine Press Ltd, 1999
14. Gingell C, Wright P, Barnes T, et al. Guidance on the management of erectile dysfunction in primary care. Prescriber 1999 Jun; Suppl. 5: 1-16
15. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997 Jun; 157: 2135-8
16. Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of goal directed therapy for impotence. J Urol 1996 May; 155 (5): 1609-12
17. National Health Service (General Medical Services) Schedule 11 Amendment (No 2) Regulations 1999, SI 1999/1627; 1999
18. Plumb JM, Guest JF. Annual cost of erectile dysfunction to UK society. Pharmacoeconomics 1999 Dec; 16 (6): 699-709
19. Tan HL. Economic cost of male erectile dysfunction using a decision analytic model: For a hypothetical managed-care plan of 100 000 members., Pharmacoeconomics 2000 Jan; 17 (1): 77-107
20. Plumb JM, Guest JF. Cost-effectiveness of Viridal Duo compared to MUSE and Viagra in the treatment of erectile dysfunction in the UK: A preliminary model. J Med Econ 1999; 2: 65-83
21. Stolk EA, Busshbach JJ, Caffa M, et al. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. BMJ 2000 Apr 29; 320 (7234): 1165-8
22. British National Formulary. Vol 39, March 2000 section 7.4.5. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2000
23. Department of Health. Prescription Cost Analysis 1997, 1998, 1999 and 2000 [Online]. Available from URL: http://www.doh.gov.uk/prescriptionstatistics/index.htm [Accessed 2000 Oct 19]
24. Office of National Statistics (ONS). Population Trends 105. United Kingdom 2001 [online]. Available from URL: http://www.statistics.gov.uk/statbase/xsdataset.asp?.vInk= 4891&B3.x=72&B3.y=17 [Accessed 2000 Oct 19]
25. Department of Health. Hospital episode statistics. United Kingdom 2000 [online]. Available from URL: http://www.doh.gov.uk/hes/standard_data/available_tables/all_ tables/index.html [Accessed 2000 Oct 19]
26. Frost and Sullivan Ltd. European Erectile Dysfunction Therapies and Devices Market 1999 [Online]. Available from URL: http://www.frost.com [Accessed 2001 Feb 6]
27. Urology Dept, Addenbrooke's Hospital. Vacuum therapy for impotence 2001 [Patient Information Leaflet]. Cambridge, UK: Urology Dept, Addenbrooke's Hospital, 2001
28. Doctors' Independent Network (DIN-LINK) Database [Data Files]. Woking, Surrey (UK): CompuFile Ltd, 2001
29. Hackett G, Milledge D. A 12 Month Follow-Up of 260 Consecutive Patients Prescribed Sildenafil Following UK Regulations on Restricted Use [Poster 160]. Rome: ESSIR, 2001 Oct
30. Netten A, Curtis L. Unit Costs of Health and Social Care [Report]. UK: Personal Social Services Research Unit, University of Kent at Canterbury, the London School of Economics, University of Manchester, 1997
31. Netten A, Curtis L. Unit Costs of Health and Social Care [Report]. UK: Personal Social Services Research Unit, University of Kent at Canterbury, the London School of Economics, University of Manchester, 1998
32. Netten A, Curtis L. Unit Costs of Health and Social Care [Report]. UK: Personal Social Services Research Unit, University of Kent at Canterbury, the London School of Economics, University of Manchester, 1999
33. Retail Price Index. London: Office of National Statistics, 2001
34. British Association of Urological Surgeons (BAUS). Survey on the Management of Erectile Dysfunction [Survey]. London: British Association of Urological Surgeons (BAUS), 2000
35. Centers for Disease Control and Prevention, CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998 Nov 25; 280 (20): 1757-63
36. Duttagupta S, Laitinen D, Broderick W, et al. Economic impact of sildenafil citrate treatment among newly diagnosed erectile dysfunction patients in managed care organizations [abstract]. J Urol 2001; 165 (5 Suppl.): 12
37. Ferriman A. UK government finalises restrictions on Viagra prescribing. BMJ 1999 May; 318: 1305
38. Ashton-Key M, Sadler M, Arundel F, et al. Using sildenafil to treat diabetic erectile dysfunction: A cost neutral implementation in the Portsmouth district [abstract P253]. Diabetes Professional Meeting; 2001 Apr 4-6; Glasgow, Scotland
39. Wylie KR, Davies-South D. Returning an ED referral to the referrer by two different routes. Br J Urol 2001; 87: 846-8
40. Wylie KR, Pratt P, Barclay C. The introduction of a shared care protocol for erectile dysfunction. Trends in Urol, Gynae, Sexual Health 2001; 6: 23-5
41. Williams D, Feely J. Initial Uptake in Use of Sildenafil in General Practice Pharmacoepidemiology and Prescription. New York: Springer-Verlag, 2001 [online] Available from URL: http://link.springer.de/link/service/journals/00228/contents /.../s002280000255ch100.htm. [Accessed 2001 Feb 22]
42. Hedelin H, Jacobson L. Viagra first-line drug in the treatment of erectile function: A variety of methods make individual treatment possible. Läkartidningen 2000; 97 (21): 1-6
43. Freemantle N. Valuing the effects of sildenafil in erectile dysfunction: Strong assumptions are required to generate a QALY value. BMJ 2000 Apr; 320 (7243): 1156-7